missouri medicaid glp-1 to stop covering weight-loss drugs for obesity in New Hampshire • New Hampshire Bulletin GLP-1 therapies are changing obesity

Phase 2 obesity trial (NEJM 2023) adverse events by maintenance dose (where a dose had two escalation arms, the range across both arms is shown): Phase 2 type 2 diabetes trial (Lancet 2023): mild-to-moderate gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were reported in 35% of retatrutide participants ranging from 13% at 0.5 mg to 50% in the 8 mg fast-escalation group compared with 13% on placebo and 35% on dulaglutide 1.5 mg

These medications work through multiple complementary mechanisms that collectively promote weight loss and metabolic improvement

doi: 10.2147/CPAA.S374741 137 MahapatraMKKaruppasamyMSahooBM

From an integrative perspective, we always work to put lab data in the context of your health history, symptoms, and goals

-Synuclein overexpression in SH-SY5Y human neuroblastoma cells leads to the accumulation of thioflavin S-positive aggregates and impairment of glycolysis